FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922225832> ?p ?o ?g. }

• W2922225832 endingPage "2210" @default.
• W2922225832 startingPage "2210" @default.
• W2922225832 abstract "Abstract The RAS-RAF-MEK-ERK (MAPK) pathway is deregulated in many cancers including acute myeloid leukemia (AML), where it facilitates cancer progression, chemo-resistance and cancer relapse. Therefore, the inhibition of this pathway has been explored for the treatment of AML, especially in the ~10% of AML cases where the leukemic cells carry activating mutations of the NRAS or KRAS oncogenes. However, MEK inhibitors, the best explored class of MAPK inhibitors, have not proven effective in the clinical setting. A novel clinically investigated drug class in this context are the paradox-breaker pan-RAF inhibitors that prevent the reactivation of the MAPK-pathway and have exhibited single agent efficacy in preclinical testing for solid cancers. Therefore, it is relevant to explore the utility of this class of drugs for AML treatment. We found that the paradox breaker pan-RAF inhibitors LY3009120 (currently in clinical testing), AZ-628 and TAK-632 as well as other MAPK inhibitors effectively downregulated MAPK signaling activity (ERK phosphorylation) in AML cells. However, when comparing cell viability (CellTiter Glo) and cell death (CellTox Green) responses in 101 AML patient sample cohort, only the pan-RAF inhibitors induced cytotoxicity while the other MAPK-pathway inhibitors generally induced a temporary cytostatic response. Specifically, LY3009120 induced cell death in 42 samples out of 101 (42 %) whereas only 9/101 (9 %) underwent cell death in response to trametinib (MEK-inhibitor) (Fig. panel A). Importantly, LY3009120 did not induce cell death in mononuclear bone marrow cells obtained from healthy individuals (5 samples) or in non-hematopoietic cell lines (Fig. panel A). To get insight into the mechanism regulating cell death in response to pan-RAF inhibition we first characterized that cells underwent rapid caspase-3/7 mediated apoptotic cell death in response to pan-RAF inhibitors (Fig. panel B). Therefore, we analyzed the proteins involved in apoptosis pathways and found that MCL-1 protein, but not mRNA levels, were downregulated upon treatment with pan-RAF inhibitors but not with MEK-inhibitors. This suggests that pan-RAF inhibition negatively regulated the translation of MCL-1, thus uncovering a new mode of MCL-1 regulation by RAF kinases. Importantly, pan-RAF inhibitors downregulated MCL-1 levels independently of caspase activity, indicating that MCL-1 downregulation precedes the apoptotic response. We explored the link between somatic mutation status and response to LY3009120 in our AML patient sample cohort. KRAS, KIT, FLT3-TKD, BCOR, JAK2 and PTPN11 mutations were found to correlate positively with pan-RAF inhibitor response, while SRSF2, RUNX1, GATA2 and STAG2 mutations negatively correlated with response and appeared to override positively correlating mutations. As pan-RAF inhibition downregulates MCL-1, an important survival protein whose increased expression is known to cause resistance to BCL-2 inhibitors, we hypothesized that inhibition of RAF kinases can overcome the resistance to BCL-2 inhibitors. In order to test the hypothesis, we generated venetoclax (BCL-2 inhibitor) resistant MOLM-13 cells and treated them with single and combined doses of venetoclax and LY3009120. As expected, combined inhibition of BCL-2 and RAF kinases significantly increased cytotoxicity as compared to either of the drugs alone (Fig. panel C). Conversely, to see if BCL-2 inhibition can overcome resistance to pan-RAF inhibitors, we treated pan-RAF inhibitor resistant HL-60 and THP-1 cells with single and combined doses of venetoclax and LY3009120. Interestingly, the drug combination exhibited synergistic cytotoxicity in HL-60 cells (where LY3009120 alone downregulates MCL-1) but not in THP-1 cells (where LY3009120 alone does not downregulate MCL-1). This indicates that MCL-1 downregulation upon pan-RAF inhibitor treatment is critical for the observed combination cytotoxicity. In summary, our results show that paradox breaker pan-RAF inhibitors are effective as single agents to induce cell death in AML blasts, likely through a combined MAPK pathway and MCL-1 dependent mechanism. Moreover, combined inhibition of RAF kinases and BCL-2 can overcome resistance of AML cells to either drug alone and lead to superior anti-leukemic activity. Figure. Figure. Disclosures Heckman: Celgene: Research Funding; Novartis: Research Funding; Orion Pharma: Research Funding. Porkka:Novartis: Honoraria, Research Funding; Celgene: Honoraria, Research Funding. Wennerberg:Novartis: Research Funding." @default.
• W2922225832 created "2019-03-22" @default.
• W2922225832 creator A5017930232 @default.
• W2922225832 creator A5025335008 @default.
• W2922225832 creator A5050582242 @default.
• W2922225832 creator A5050873337 @default.
• W2922225832 creator A5061939140 @default.
• W2922225832 creator A5067760174 @default.
• W2922225832 date "2018-11-29" @default.
• W2922225832 modified "2023-10-01" @default.
• W2922225832 title "Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity" @default.
• W2922225832 doi "https://doi.org/10.1182/blood-2018-99-118289" @default.
• W2922225832 hasPublicationYear "2018" @default.
• W2922225832 type Work @default.
• W2922225832 sameAs 2922225832 @default.
• W2922225832 citedByCount "2" @default.
• W2922225832 countsByYear W29222258322019 @default.
• W2922225832 countsByYear W29222258322020 @default.
• W2922225832 crossrefType "journal-article" @default.
• W2922225832 hasAuthorship W2922225832A5017930232 @default.
• W2922225832 hasAuthorship W2922225832A5025335008 @default.
• W2922225832 hasAuthorship W2922225832A5050582242 @default.
• W2922225832 hasAuthorship W2922225832A5050873337 @default.
• W2922225832 hasAuthorship W2922225832A5061939140 @default.
• W2922225832 hasAuthorship W2922225832A5067760174 @default.
• W2922225832 hasBestOaLocation W29222258321 @default.
• W2922225832 hasConcept C121608353 @default.
• W2922225832 hasConcept C126322002 @default.
• W2922225832 hasConcept C184235292 @default.
• W2922225832 hasConcept C190283241 @default.
• W2922225832 hasConcept C203014093 @default.
• W2922225832 hasConcept C21790070 @default.
• W2922225832 hasConcept C2778461978 @default.
• W2922225832 hasConcept C2778472372 @default.
• W2922225832 hasConcept C2778729363 @default.
• W2922225832 hasConcept C2781187634 @default.
• W2922225832 hasConcept C2781249067 @default.
• W2922225832 hasConcept C31573885 @default.
• W2922225832 hasConcept C502942594 @default.
• W2922225832 hasConcept C526805850 @default.
• W2922225832 hasConcept C55493867 @default.
• W2922225832 hasConcept C57074206 @default.
• W2922225832 hasConcept C71924100 @default.
• W2922225832 hasConcept C86803240 @default.
• W2922225832 hasConcept C95444343 @default.
• W2922225832 hasConcept C96232424 @default.
• W2922225832 hasConcept C98274493 @default.
• W2922225832 hasConceptScore W2922225832C121608353 @default.
• W2922225832 hasConceptScore W2922225832C126322002 @default.
• W2922225832 hasConceptScore W2922225832C184235292 @default.
• W2922225832 hasConceptScore W2922225832C190283241 @default.
• W2922225832 hasConceptScore W2922225832C203014093 @default.
• W2922225832 hasConceptScore W2922225832C21790070 @default.
• W2922225832 hasConceptScore W2922225832C2778461978 @default.
• W2922225832 hasConceptScore W2922225832C2778472372 @default.
• W2922225832 hasConceptScore W2922225832C2778729363 @default.
• W2922225832 hasConceptScore W2922225832C2781187634 @default.
• W2922225832 hasConceptScore W2922225832C2781249067 @default.
• W2922225832 hasConceptScore W2922225832C31573885 @default.
• W2922225832 hasConceptScore W2922225832C502942594 @default.
• W2922225832 hasConceptScore W2922225832C526805850 @default.
• W2922225832 hasConceptScore W2922225832C55493867 @default.
• W2922225832 hasConceptScore W2922225832C57074206 @default.
• W2922225832 hasConceptScore W2922225832C71924100 @default.
• W2922225832 hasConceptScore W2922225832C86803240 @default.
• W2922225832 hasConceptScore W2922225832C95444343 @default.
• W2922225832 hasConceptScore W2922225832C96232424 @default.
• W2922225832 hasConceptScore W2922225832C98274493 @default.
• W2922225832 hasIssue "Supplement 1" @default.
• W2922225832 hasLocation W29222258321 @default.
• W2922225832 hasOpenAccess W2922225832 @default.
• W2922225832 hasPrimaryLocation W29222258321 @default.
• W2922225832 hasRelatedWork W2003360338 @default.
• W2922225832 hasRelatedWork W2164992866 @default.
• W2922225832 hasRelatedWork W2261929084 @default.
• W2922225832 hasRelatedWork W2741144734 @default.
• W2922225832 hasRelatedWork W2741536934 @default.
• W2922225832 hasRelatedWork W2787335541 @default.
• W2922225832 hasRelatedWork W2920147611 @default.
• W2922225832 hasRelatedWork W2992595709 @default.
• W2922225832 hasRelatedWork W3022164378 @default.
• W2922225832 hasRelatedWork W4200179277 @default.
• W2922225832 hasVolume "132" @default.
• W2922225832 isParatext "false" @default.
• W2922225832 isRetracted "false" @default.
• W2922225832 magId "2922225832" @default.
• W2922225832 workType "article" @default.